Akums Drugs & Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,158Cr
- +9.7% YoY
- −0.2% QoQ
- Net profit
- ₹81Cr
- −46% YoY
- +19.1% QoQ
- Margin
- 13%
- +4 pp YoY
- 0 pp QoQ
Guidance rank: #25 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).
From Akums Drugs & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- European CDMO contract projected to contribute around EUR35 million annually from FY28, adding to revenue.
- Anticipated improvement in CDMO margins to mid-teens (15-16%) as international contracts scale up.
- Domestic formulations expected to grow in line with Indian Pharmaceutical Market (IPM) with double-digit top-line growth driven by volume, price, and NII growth.
- Trade generics expected to reduce EBITDA losses sizably with a goal to achieve monthly positive EBITDA within a few quarters.
- Oral solid facility expansion underway to support volume growth.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.
- Ongoing expansion of the oral solid facility to support over 20% volume growth.
- Investment in ramping up new injectable, Penem, and Baddi plants progressing with client audits and product approvals underway.
- Focus is on utilizing existing advanced injectable and hormone facilities.
- Evaluating inorganic opportunities in branded portfolios, though current market valuations are high.
- SAP S/4HANA digital transformation and Darwinbox HR implementation underway for operational efficiency.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is actively engaged with 8 to 10 global CDMO customers expected over the next 2-3 years.
- For FY28, export CDMO revenues are projected around EUR70 million (approximately INR680 crores).
- The European contract alone is expected to deliver about EUR35 million on a MAT basis annually starting FY28.
- The Zambia contract will contribute approximately $25 million annually in FY27 and FY28.
- These long-term contracts have a ramp-up period of 2-3 years due to dossier clearances and regulatory approvals.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Akums Drugs & Pharmaceuticals Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,158 | 1,056 | +9.7% | 1,160 | -0.2% |
| Operating profit (EBITDA) | 152 | 94 | +61.7% | 147 | +3.4% |
| Operating margin | 13% | 9% | +4 pp | 13% | 0 pp |
| Profit before tax | 121 | 75 | +61.3% | 100 | +21% |
| Net profit (PAT) | 81 | 150 | -46% | 68 | +19.1% |
| EPS (₹) | 5.38 | 9.38 | -42.6% | 4.21 | +27.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q4 FY26 results?
CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
